Related Experiment Videos
[Defibrination treatment of progressive scleroderma].
Phlebologie
|January 1, 1979
Summary
Defibrination therapy using Arwin showed positive clinical results in 9 of 16 patients with systemic sclerosis. Objective measures are pending, but this enzyme preparation offers potential for treating this progressive condition.
Area of Science:
- Rheumatology
- Vascular Biology
- Enzyme Therapy
Background:
- Scleroderma progressiva is a debilitating autoimmune disease.
- Current therapeutic options for scleroderma progressiva are limited.
- Defibrination therapy presents a novel treatment approach.
Purpose of the Study:
- To evaluate the efficacy of Arwin, an enzyme preparation, as a defibrination therapy.
- To assess clinical outcomes in patients with scleroderma progressiva treated with Arwin.
- To investigate objective markers of Arwin's therapeutic effect.
Main Methods:
- A cohort of 16 patients with scleroderma progressiva received Arwin therapy.
- Clinical assessments were performed to evaluate treatment response.
- Venous occlusion plethysmography and Technetium-99 isotope imaging with a Gamma-camera were utilized for objective measurements.
Main Results:
- Nine patients (56%) demonstrated a clinically good response to Arwin therapy.
- Three patients (19%) showed some improvement, though objective data were inconclusive.
- Four patients (25%) exhibited no clinical or objective response to the treatment.
Conclusions:
- Arwin defibrination therapy shows promise in a subset of patients with scleroderma progressiva.
- Further objective investigations are warranted to fully elucidate Arwin's therapeutic potential.
- Patient response to Arwin therapy appears variable, necessitating personalized treatment strategies.